FCPB must have a negative urine or serum pregnancy test within  days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program\r\n* NOTE: should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
All study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
Must be willing and able to adhere to pomalidomide-related risk mitigation activities if randomized to the pomalidomide+dexamethasone (pom+dex) arm (e.g., Risk Evaluation and Mitigation Strategies [REMS], pregnancy prevention programs).
All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants be willing and able to comply with the requirements of the Risk Evaluation and Mitigation Strategies (REMS) program
Registered into mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of Rems
All study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program